Reaction Biology Corporation

reactionbiology.com

Reaction Biology Corp. (“RBC”) is a premier service provider for drug profiling, screening and early-stage drug discovery collaborations. Its proprietary HotSpot technology is an innovative platform for screening/profiling small molecules vs biological target assayable by radioisotope detection. For kinase and transferase enzymes in particular, such assays are the “gold standard”. RBC screens and profiles vs all major classes of epigenetic transferases via the radioisotope approach—HMTs, DNMTs, HATs, and also over 600 kinases. HotSpot assay substrates require no special modifications (e.g. biotin, fluorophors or other tags). Hence biologically relevant substrates may be used, including full nucleosomes, histone proteins or peptides. Since detection does not rely on antibodies, coupling enzymes or fluorescence, major causes of false positives, false negatives and compound interference are eliminated.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

BOOST BIOMES ANNOUNCES CLOSE OF SERIES A AND CO-DEVELOPMENT AGREEMENT WITH LEAD INVESTOR, YARA INTERNATIONAL, FOR BIOSTIMULANTS PRODUCTS

Boost Biomes | June 25, 2020

news image

US-based food and agriculture biotech startup Boost Biomes and global crop nutrition company, Yara International ASA, announced today the close of Boost's USD 5 million series A equity round as well as a joint development agreement between the two companies. Yara's investment amounts to USD 3 million. Existing investors, including Viking Global Investors and Y Combinator, participated in the close.With this partnership in place, Boost and Yara will expand current efforts to co-deve...

Read More

CELL AND GENE THERAPY, INDUSTRIAL IMPACT

CARIS LIFE SCIENCES AND INCYTE ANNOUNCE STRATEGIC RESEARCH PARTNERSHIP

Caris Life Sciences | March 09, 2023

news image

Caris Life Sciences®, a leading molecular science and technology firm and Incyte Corporation have recently announced a strategic research partnership to advance precision medicine approaches for Incyte's oncology pipeline. Caris' innovative technology integrates data from whole exome sequencing, protein analysis, whole transcriptome sequencing and proprietary AI models and signatures to enhance patient outcomes through personalized medicine development. Th...

Read More

CELL AND GENE THERAPY, INDUSTRIAL IMPACT

ALDEVRON LAUNCHES TYPE-V CRISPR NUCLEASE, EURECA-V™ MAD7®

Aldevron | January 20, 2023

news image

Aldevron®, a worldwide leader in the custom development and production of plasmid DNA, RNA, and proteins for the biotech sector, recently announced the launch of Eureca-V™ nuclease. Eureca-V™, licensed from Inscripta®, is the wild-type MAD7® CRISPR Type-V nuclease at research grade, with GMP to follow. The launch of Aldevron's Eureca-V nuclease at advanced therapies week expands the toolkit of accessible CRISPR nucleases for therapeutic, di...

Read More

ALLIGATOR BIOSCIENCE PRESENTS POSITIVE BIOMARKER DATA DEMONSTRATING PROOF OF MECHANISM IN MITAZALIMAB CLINICAL PHASE I STUDY

PR Newswir | September 04, 2020

news image

Alligator Bioscience (Nasdaq Stockholm: ATORX) announced today biomarker data from a recently performed clinical Phase I study of the drug candidate mitazalimab, its wholly owned CD40 antibody in development primarily for the treatment of pancreatic cancer. The data will be presented today at the scientific conference PEGS: The Essential Protein Engineering Summit being held virtually August 31- September 4, 2020."The presented biomarker data confirm the proof of mechanism and strengt...

Read More
news image

BOOST BIOMES ANNOUNCES CLOSE OF SERIES A AND CO-DEVELOPMENT AGREEMENT WITH LEAD INVESTOR, YARA INTERNATIONAL, FOR BIOSTIMULANTS PRODUCTS

Boost Biomes | June 25, 2020

US-based food and agriculture biotech startup Boost Biomes and global crop nutrition company, Yara International ASA, announced today the close of Boost's USD 5 million series A equity round as well as a joint development agreement between the two companies. Yara's investment amounts to USD 3 million. Existing investors, including Viking Global Investors and Y Combinator, participated in the close.With this partnership in place, Boost and Yara will expand current efforts to co-deve...

Read More
news image

CELL AND GENE THERAPY, INDUSTRIAL IMPACT

CARIS LIFE SCIENCES AND INCYTE ANNOUNCE STRATEGIC RESEARCH PARTNERSHIP

Caris Life Sciences | March 09, 2023

Caris Life Sciences®, a leading molecular science and technology firm and Incyte Corporation have recently announced a strategic research partnership to advance precision medicine approaches for Incyte's oncology pipeline. Caris' innovative technology integrates data from whole exome sequencing, protein analysis, whole transcriptome sequencing and proprietary AI models and signatures to enhance patient outcomes through personalized medicine development. Th...

Read More
news image

CELL AND GENE THERAPY, INDUSTRIAL IMPACT

ALDEVRON LAUNCHES TYPE-V CRISPR NUCLEASE, EURECA-V™ MAD7®

Aldevron | January 20, 2023

Aldevron®, a worldwide leader in the custom development and production of plasmid DNA, RNA, and proteins for the biotech sector, recently announced the launch of Eureca-V™ nuclease. Eureca-V™, licensed from Inscripta®, is the wild-type MAD7® CRISPR Type-V nuclease at research grade, with GMP to follow. The launch of Aldevron's Eureca-V nuclease at advanced therapies week expands the toolkit of accessible CRISPR nucleases for therapeutic, di...

Read More
news image

ALLIGATOR BIOSCIENCE PRESENTS POSITIVE BIOMARKER DATA DEMONSTRATING PROOF OF MECHANISM IN MITAZALIMAB CLINICAL PHASE I STUDY

PR Newswir | September 04, 2020

Alligator Bioscience (Nasdaq Stockholm: ATORX) announced today biomarker data from a recently performed clinical Phase I study of the drug candidate mitazalimab, its wholly owned CD40 antibody in development primarily for the treatment of pancreatic cancer. The data will be presented today at the scientific conference PEGS: The Essential Protein Engineering Summit being held virtually August 31- September 4, 2020."The presented biomarker data confirm the proof of mechanism and strengt...

Read More